TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2492597
Drug: Human milk
Normalized name: HUMAN MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human milk preparation (14 mL/kg/d for 2 weeks)
Study: 2492597
Drug: Sterile water
Normalized name: sterile water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile water (14 mL/kg/d for 2 weeks)
Study: 29927279
Drug: Both DT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both DT and ST treatments included transdermal nicotine patch and structured sessions.
Study: 19164205
Drug: Erlotinib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib 300 mg
Study: 17364629
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of superactivated charcoal (50 g)
Study: 17364629
Drug: Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of superactivated charcoal (50 g, six doses q4h)
Study: 11075558
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) group
Study: 11075558
Drug: Conventional continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional continuous infusion (Cont group)
Study: 1300957
Drug: rt PA
Normalized name: ATTENDS INSERT PAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: rt PA (10 mg bolus followed by 90 mg in 130 mn)
Study: 3840066
Drug: Acrivastine (BW825C)
Normalized name: Acrivastine
DrugBank: Acrivastine (DB09488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acrivastine (BW825C) 4 mg, 8 mg, and 16 mg
Study: 3840066
Drug: Triprolidine HCl
Normalized name: Triprolidine HCl
DrugBank: Triprolidine (DB00427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triprolidine HCl 2.5 mg and 5 mg
Study: 30648677
Drug: GA +
Normalized name: Sea-Omega + D Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA + intravenous analgesia (Group II)
Study: 30098042
Drug: Pimodivir 600
Normalized name: Pimodivir
DrugBank: Pimodivir (DB14974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimodivir 600 mg with oseltamivir 75 mg
Study: 24874893
Drug: Adalimumab (dose-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (dose-escalation subcohort)
Study: 20598967
Drug: Prasugrel +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel + aspirin
Study: 15818103
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume ventilation (6 mL/kg of predicted body weight)
Study: 15818103
Drug: Higher tidal
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher tidal volume ventilation (12 mL/kg of predicted body weight)
Study: 7634133
Drug: Delmopinol hydrochloride
Normalized name: delmopinol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delmopinol hydrochloride solution (2 mg/ml) rinsing for 60 s twice daily
Study: 2792175
Drug: digoxin and
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: digoxin and concomitant treatment with urapidil 60 mg b.d.
Study: 2792175
Drug: digoxin monotherapy
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: digoxin monotherapy
Study: 356508
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam combined with intramuscular administration of vehicle used in Group B (Group C)
Study: 22261128
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (1 capsule daily for 3 months)
Study: 20039078
Drug: Ketamine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1.0 mg kg(‐1)
Study: 16353968
Drug: Gelled self-emulsifying
Normalized name: marine non-gelling gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelled self-emulsifying formulation (SEF) containing ketoprofen (KPF)
Study: 16353968
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release solid dosage form
Study: 12559482
Drug: Low-dose physostigmine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose physostigmine (PHYSO) 8 microg/kg IV
Study: 2480243
Drug: Streptozocin plus
Normalized name: Streptozocin
DrugBank: Streptozocin (DB00428)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Streptozocin plus 5‐fluorouracil (chemotherapy)
Study: 229780
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) for 28 days
Study: 229780
Drug: Total Parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total Parenteral Nutrition (TPN) for less than 9-14 days
Study: 229780
Drug: Intensive Nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive Nutritional Counseling (INC) and oral supplementation
Study: 30994576
Drug: Vaginal 10
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal 10 μg estradiol tablet plus placebo gel (n = 102)
Study: 30994576
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet plus vaginal moisturizer (n = 100)
Study: 28341129
Drug: Hand washing
Normalized name: ALCOHOL 350 mL in 500 mL EXTRACORPOREAL GEL [75% alcohol free hand washing gel]
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand washing with alcohol gel only up to elbows (Group A)
Study: 28341129
Drug: Hand washing
Normalized name: ALCOHOL 350 mL in 500 mL EXTRACORPOREAL GEL [75% alcohol free hand washing gel]
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand washing with soap up to elbows, sterile towel to dry, followed by alcohol gel (Group B)
Study: 28341129
Drug: Hand washing
Normalized name: ALCOHOL 350 mL in 500 mL EXTRACORPOREAL GEL [75% alcohol free hand washing gel]
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand washing with soap up to elbows, non‐sterile towel to dry, followed by alcohol gel (Group C)
Study: 24418055
Drug: ABT-384 10
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-384 10 mg once daily
Study: 24418055
Drug: ABT-384 50
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-384 50 mg once daily
Study: 29854928
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg once daily
Study: 22048324
Drug: L-arginine (4.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (4.25 mmol L(‐1))
Study: 22048324
Drug: L-glutamine (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (45 mmol L(‐1))
Study: 17488518
Drug: Pemetrexed 500
Normalized name: pemetrexed 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 500 mg/m2 d1 and cisplatin 75 mg/m2 d1, q 3 weeks
Study: 12127641
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg orally followed by misoprostol 0.8 mg orally or vaginally 36-48 hours later
Study: 9667273
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg methylphenidate twice daily
Study: 9667273
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg methylphenidate twice daily
Study: 9667273
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg methylphenidate twice daily
Study: 9667273
Drug: methylphenidate treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate treatment
Study: 8137524
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg cetrorelix
Study: 8137524
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg cetrorelix
Study: 8137524
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg cetrorelix
Study: 22891232
Drug: FSV/TPGS preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSV/TPGS preparation coadministered with additional vitamin K
Study: 22891232
Drug: FSV/TPGS preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: FSV/TPGS preparation
Study: 20543018
Drug: On-call physical
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-call physical therapy
Study: 20543018
Drug: Regular physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular physical therapy (Control)
Study: 17720303
Drug: Moderate atherosclerosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate atherosclerosis (no specific treatment mentioned)
Study: 15925748
Drug: L-NMMA (intra-arterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (intra-arterial infusion of 4 micromol/min)
Study: 12885701
Drug: Bread and
Normalized name: Low protein bread and bread rolls
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bread and cookies rich in beta-glucan (5.9 g/day)
Study: 12885701
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice containing beta-glucan (5 g/day)
Study: 1482265
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (CEI)
Study: 1482265
Drug: Calcium antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonists (CA)
Study: 3912334
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg i.v. indoprofen
Study: 3912334
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg i.m. morphine hydrochloride
Study: 31679509
Drug: Intermittent boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent boluses (1.5 mcg/Kg phenylephrine)
Study: 31679509
Drug: Fixed on-and-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed on-and-off infusion (0.75 mcg/Kg/min)
Study: 31679509
Drug: Variable infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Variable infusion (0.75 mcg/Kg/min)
Study: 15718305
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m² once every 3 weeks
Study: 10340423
Drug: Intrathecal baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal baclofen (50 microg bolus injection)
Study: 31039763
Drug: BM-MSCs treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BM-MSCs treatment
Study: 26669546
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement (25 patients)
Study: 26669546
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement (25 patients)
Study: 12195603
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide 40 micro g four times daily
Study: 9578047
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg midazolam (MDL) in 2 ml peppermint-flavored fluid
Study: 10522780
Drug: Controlled-release of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release of subgingivally delivered doxycycline hyclate in a polylactic acid based polymer gel
Study: 2072698
Drug: Intraluminal radiotherapy
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraluminal radiotherapy (ILRT) plus concurrent 5-fluorouracil (5-FU) infusion
Study: 6849205
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg metronidazole intravenously every 6 hours for three doses
Study: 30730785
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of folic acid for 16 weeks
Study: 29573207
Drug: Rolontis 270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolontis 270 μg/kg
Study: 29573207
Drug: Rolontis 135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolontis 135 μg/kg
Study: 29573207
Drug: Rolontis 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rolontis 45 μg/kg
Study: 26853325
Drug: Dexamethasone (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (12 mg/day for 3 weeks followed by tapering)
Study: 19864114
Drug: First-generation antipsychotic
Normalized name: benzethonium chloride / lidocaine hydrochloride Topical Gel [Tecnu First Aid]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation antipsychotic (perphenazine)
Study: 19864114
Drug: Second-generation antipsychotic
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation antipsychotic (quetiapine)
Study: 11896327
Drug: PEN110 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEN110 treatment (pathogen-inactivated RBCs)
Study: 11896327
Drug: PEN110 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEN110 treatment
Study: 27650139
Drug: Lip training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lip training with 200 or 400 g of bottled water in the oral vestibule
Study: 25183507
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of rosemary essential oil for three minutes
Study: 25183507
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of lavender essential oil for three minutes
Study: 25183507
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of eucalyptus essential oil for three minutes
Study: 22613015
Drug: Intervention A
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention A (written information - leaflet describing correct inhalation techniques)
Study: 22613015
Drug: Intervention B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention B (written information about inhalation techniques plus training by an instructor)
Study: 16439851
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (1 or 2 mg/m2/day)
Study: 11593632
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of tPA (Group I; n = 26)
Study: 1376503
Drug: Monoclonal antibody
Normalized name: Monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibody staining of needle core biopsies (MABS)
Study: 29210808
Drug: Haloperidol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (1 mg twice daily for 7 days)
Study: 29210808
Drug: Placebo (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (twice daily for 7 days)
Study: 22126416
Drug: IgE-antibody to
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE-antibody to Ara h 1, 2, and 3
Study: 19522751
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg/day for 9 days after bout 1)
Study: 18630774
Drug: Caffeine benzoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine benzoate, 20 mg/kg IV
Study: 12122787
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ESWT, 2000 pulses, energy flux density ED+ 0.1 mJ/mm2, 3 times in 1 week intervals)
Study: 10607226
Drug: Consensus interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consensus interferon (IFN) treatment
Study: 10607226
Drug: IFN‐alpha2b treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN‐alpha2b treatment
Study: 913045
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of adrenaline
Study: 31018017
Drug: Person‐Centred Experiential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Person‐Centred Experiential Therapy (PCET)
Study: 28687551
Drug: Nebulized morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine 20 mg every 4 hours
Study: 28687551
Drug: Nebulized fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nebulized fentanyl 25 and 100 μg
Study: 28687551
Drug: Nebulized hydromorphone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hydromorphone 5 mg
Study: 28687551
Drug: Nebulized morphine-6-glucuronide
Normalized name: MENTHOL GLUCURONIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized morphine-6-glucuronide
Study: 28687551
Drug: Other nebulized
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other nebulized opioids (various doses)
Study: 25047796
Drug: Intravenous dexketoprofen
Normalized name: dexketoprofen
DrugBank: Dexketoprofen (DB09214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexketoprofen trometamol (50 mg) and intraarticular normal saline (20 mL)
Study: 25047796
Drug: Intraarticular 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular 0.5 % levobupivacaine (100 mg) and intravenous normal saline (2 mL)
Study: 25047796
Drug: Intraarticular 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular 0.5 % levobupivacaine (100 mg) and intravenous dexketoprofen trometamol (50 mg)
Study: 15684155
Drug: Dilute oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dilute oxytocin infusion (10 IU in 500 mL saline at 125 mL/h)
Study: 12851521
Drug: Continuous‐combined hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous‐combined hormone replacement therapy (0.625 mg/day conjugated equine estrogen plus 5 mg/day medroxyprogesterone)
Study: 12851521
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no HRT treatment)
Study: 6758933
Drug: Tiapamil (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (intravenous and/or oral)
Study: 29228473
Drug: Desvenlafaxine (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (50, 100, and 200 mg)
Study: 27043082
Drug: Losmapimod (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losmapimod (7.5 mg, twice daily)
Study: 20557835
Drug: S-etodolac ER
Normalized name: etodolac Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-etodolac ER 300 mg
Study: 20557835
Drug: etodolac ER
Normalized name: Etodolac ER
DrugBank: Etodolac (DB00749)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: etodolac ER 600 mg
Study: 12817528
Drug: Repaglinide with
Normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Repaglinide with strong inhibitors or inducers of CYP3A4
Study: 2057103
Drug: phytostimolin cream
Normalized name: thymostimulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: phytostimolin cream and vaginal lavage
Study: 6337761
Drug: Indenolol (30-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indenolol (30- or 60-mg tablets, twice daily for 14 days)
Study: 26628249
Drug: Multisystemic Therapy‐Health
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multisystemic Therapy‐Health Care (MST‐HC)
Study: 22270216
Drug: Prednisone (steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (steroid group) for 15 days starting with 100 mg at surgery, tapered to 12.5 mg.
Study: 22270216
Drug: Placebo (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (control group) administered in a comparable manner to the steroid group.
Study: 22270216
Drug: Prednisone (steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (steroid group)
Study: 17207145
Drug: Future use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Future use of the Vi vaccine
Study: 10554747
Drug: Prilocaine plus
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prilocaine plus lidocaine cream (Group A)
Study: 10554747
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (Group B)
Study: 1659601
Drug: Immunoblot assay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunoblot assay using recombinant-baculovirus-expressed glycoprotein G (gG1 or gG2)
Study: 27884853
Drug: Gyejibongneyong-hwan (GBH)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gyejibongneyong-hwan (GBH) administered three times per day for two menstrual periods (8 weeks)
Study: 27884853
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times per day for two menstrual periods (8 weeks)
Study: 15908760
Drug: Cream preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream preparations containing marigold and rosemary extracts
Study: 15908760
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (postirritation) once a day for 5 days
Study: 9667295
Drug: Head-up position
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-up position (after norepinephrine or phenylephrine infusion)
Study: 7660342
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 200 micrograms aqueous nasal spray administered twice daily for two weeks
Study: 996687
Drug: Oral oxamniquine
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxamniquine at a total dose of 60 mg/kg (given in 4 equal doses morning and evening over 2 days, after food)
Study: 996687
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses or shorter schedules of treatment
Study: 996687
Drug: Oral oxamniquine
Normalized name: oxamniquine
DrugBank: Oxamniquine (DB01096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral oxamniquine
Study: 26016699
Drug: Itraconazole 200
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200 mg/daily for 1 week and then for the first 2 days of every month for the following 3 months